Lilly over Novo in GLP-1 race
The speaker argued Eli Lilly is the preferred investment over Novo Nordisk in the weight loss drug space, framing it as the winner likely to keep winning.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.